101
|
Nicolas J, Couvreur P. [Polymer nanoparticles for the delivery of anticancer drug]. Med Sci (Paris) 2017; 33:11-17. [PMID: 28120750 DOI: 10.1051/medsci/20173301003] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Nanocarriers based on polymers are currently attracting much attention to perform efficient drug delivery, especially in cancer therapy. Over the last decades, different kinds of polymer nanoparticulate systems have been developed (e.g., simple, stealth, targeted, stimuli-responsive and prodrug) to propose novel, better and safer cancer therapies. This article will give a brief overview of the different classes of polymer nanoparticles that have been reported and discuss some key achievements deriving from their use in the field of cancer therapy.
Collapse
Affiliation(s)
- Julien Nicolas
- Institut Galien Paris-Sud, UMR CNRS 8612, Université Paris-Sud, Faculté de Pharmacie, 5, rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France
| | - Patrick Couvreur
- Institut Galien Paris-Sud, UMR CNRS 8612, Université Paris-Sud, Faculté de Pharmacie, 5, rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry Cedex, France
| |
Collapse
|
102
|
Kim JE, Park YJ. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer. Int J Nanomedicine 2017; 12:645-658. [PMID: 28176896 PMCID: PMC5261556 DOI: 10.2147/ijn.s124158] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Paclitaxel-loaded hyaluronan solid nanoemulsions (PTX-HSNs) were successfully fabricated for the delivery of PTX to improve ovarian cancer treatment via active tumor targeting. PTX-HSNs were fabricated using high-pressure homogenization with a microfluidizer and were lyophilized with d-mannitol. Hyaluronan was coated on the outside of the PTX-HSN sphere. The mean size of the PTX-HSNs was maintained less than 100 nm, with a relatively narrow size distribution. The PTX loading content was 3 mg/mL, and encapsulation efficiency (EE) was close to 100%. In vitro cell affinity studies using SK-OV-3 (cluster of differentiation 44 [CD44+]) and OVCAR-3 (CD44−) cells showed that PTX-HSN had a targeting capability hundredfold higher than that of PTX-loaded solid nanoemulsions (PTX-SNs) without hyaluronan. Further, the in vitro PTX release by PTX-SNs and PTX-HSNs lasted more than 6 days without showing a release burst, which was more sustained than that of Taxol®, suggesting a more constant effect on cancer cells at the tumor site than was observed for Taxol. The in vivo toxicity, in vivo antitumor effects, and pharmacokinetics of PTX-HSNs and Taxol were evaluated in nude mice and rats. The maximum tolerated dose (MTD) for PTX-HSNs, PTX-SNs, and Taxol was determined by measuring changes in clinical symptoms after administering 20–50 mg/kg PTX via the caudal vein. The MTD of PTX-HSNs had a dosing capacity greater than 50 mg PTX/kg, which was 2.5-fold higher than that of Taxol when administered as a PTX injection. In vivo, PTX-HSN treatment effectively inhibited tumor growth and showed less toxicity in tumor-transplanted mice compared to that observed for Taxol treatments. The pharmacokinetic parameters of PTX-HSNs were more desirable than those of Taxol. After PTX-HSN treatment, the circulation time of PTX was prolonged and retention of PTX in ovarian tumor tissues increased. Therefore, PTX-HSN is a highly effective nanosystem with a high MTD for delivering PTX to ovarian cancers characterized by CD44 overexpression, enhanced active tumor targeting, and low toxicity.
Collapse
Affiliation(s)
- Joo-Eun Kim
- College of Pharmacy, Ajou University, Suwon City, Republic of Korea
| | - Young-Joon Park
- College of Pharmacy, Ajou University, Suwon City, Republic of Korea
| |
Collapse
|
103
|
Li L, Schmitt M, Matzke‐Ogi A, Wadhwani P, Orian‐Rousseau V, Levkin PA. CD44v6-Peptide Functionalized Nanoparticles Selectively Bind to Metastatic Cancer Cells. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2017; 4:1600202. [PMID: 28105395 PMCID: PMC5238741 DOI: 10.1002/advs.201600202] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Indexed: 05/31/2023]
Abstract
CD44v6 peptide functionalized nanoparticles are fabricated in a facile and controllable way to selectively bind to CD44v6 positive tumor cells with highly efficient anticancer and antimetastatic properties. The reported modular synthesis and facile preparation makes this system highly potent for developing novel multifunctional nanocarriers for therapeutic and/or diagnostic anticancer applications.
Collapse
Affiliation(s)
- Linxian Li
- Institute of Toxicology and GeneticsKarlsruhe Institute of Technology76344KarlsruheGermany
- Institute of Organic ChemistryUniversity of Heidelberg69120HeidelbergGermany
| | - Mark Schmitt
- Institute of Toxicology and GeneticsKarlsruhe Institute of Technology76344KarlsruheGermany
| | - Alexandra Matzke‐Ogi
- Institute of Toxicology and GeneticsKarlsruhe Institute of Technology76344KarlsruheGermany
| | - Parvesh Wadhwani
- Institute of Biological Interfaces (IBG‐2)Karlsruhe Institute of Technology76344KarlsruheGermany
| | | | - Pavel A. Levkin
- Institute of Toxicology and GeneticsKarlsruhe Institute of Technology76344KarlsruheGermany
- Department of Applied Physical ChemistryUniversity of Heidelberg69120HeidelbergGermany
| |
Collapse
|
104
|
Saber MM, Bahrainian S, Dinarvand R, Atyabi F. Targeted drug delivery of Sunitinib Malate to tumor blood vessels by cRGD-chiotosan-gold nanoparticles. Int J Pharm 2016; 517:269-278. [PMID: 27956189 DOI: 10.1016/j.ijpharm.2016.12.016] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2016] [Revised: 12/06/2016] [Accepted: 12/08/2016] [Indexed: 12/26/2022]
Abstract
The unique characteristics of tumor vasculature represent an attractive strategy for targeted delivery of antitumor and antiangiogenic agents to the tumor. The purpose of this study was to prepare c(RGDfK) labeled chitosan capped gold nanoparticles [cRGD(CS-Au) NPs] as a carrier for selective intracellular delivery of Sunitinib Malate (STB) to the tumor vasculature. cRGD(CS-Au) NPs was formed by electrostatic interaction between cationic CS and anionic AuNPs. cRGD modified CS-Au NPs had a spherical shape with a narrow size distribution. The entrapment efficiency of sunitinib molecule was found to be 45.2%±2.05. Confocal microscopy showed enhanced and selective uptake of cRGD(CS-Au) NPs into MCF-7 and HUVEC cells compared with non-targeted CS-Au NPs. Our results suggest that it may be possible to use cRGD(CS-Au) NPs as a carrier for delivery of anticancer drugs, genes and biomolecules for inhibiting tumor vasculature.
Collapse
Affiliation(s)
- Mohaddeseh Mahmoudi Saber
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Sara Bahrainian
- Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Rassoul Dinarvand
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Fatemeh Atyabi
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
105
|
Wang J, Yin Z, Xue X, Kundu SC, Mo X, Lu S. Natural Non-Mulberry Silk Nanoparticles for Potential-Controlled Drug Release. Int J Mol Sci 2016; 17:ijms17122012. [PMID: 27916946 PMCID: PMC5187812 DOI: 10.3390/ijms17122012] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Revised: 11/25/2016] [Accepted: 11/26/2016] [Indexed: 01/31/2023] Open
Abstract
Natural silk protein nanoparticles are a promising biomaterial for drug delivery due to their pleiotropic properties, including biocompatibility, high bioavailability, and biodegradability. Chinese oak tasar Antheraea pernyi silk fibroin (ApF) nanoparticles are easily obtained using cations as reagents under mild conditions. The mild conditions are potentially advantageous for the encapsulation of sensitive drugs and therapeutic molecules. In the present study, silk fibroin protein nanoparticles are loaded with differently-charged small-molecule drugs, such as doxorubicin hydrochloride, ibuprofen, and ibuprofen-Na, by simple absorption based on electrostatic interactions. The structure, morphology and biocompatibility of the silk nanoparticles in vitro are investigated. In vitro release of the drugs from the nanoparticles depends on charge-charge interactions between the drugs and the nanoparticles. The release behavior of the compounds from the nanoparticles demonstrates that positively-charged molecules are released in a more prolonged or sustained manner. Cell viability studies with L929 demonstrated that the ApF nanoparticles significantly promoted cell growth. The results suggest that Chinese oak tasar Antheraea pernyi silk fibroin nanoparticles can be used as an alternative matrix for drug carrying and controlled release in diverse biomedical applications.
Collapse
Affiliation(s)
- Juan Wang
- National Engineering Laboratory for Modern Silk, College of Textile and Clothing Engineering, Soochow University, Suzhou 215123, China.
- College of Chemistry and Chemical Engineering and Biological Engineering, Donghua University, Shanghai 201620, China.
| | - Zhuping Yin
- National Engineering Laboratory for Modern Silk, College of Textile and Clothing Engineering, Soochow University, Suzhou 215123, China.
| | - Xiang Xue
- National Engineering Laboratory for Modern Silk, College of Textile and Clothing Engineering, Soochow University, Suzhou 215123, China.
| | - Subhas C Kundu
- Department of Biotechnology, Indian Institute of Technology Kharagpur, West Bengal 721302, India.
| | - Xiumei Mo
- College of Chemistry and Chemical Engineering and Biological Engineering, Donghua University, Shanghai 201620, China.
| | - Shenzhou Lu
- National Engineering Laboratory for Modern Silk, College of Textile and Clothing Engineering, Soochow University, Suzhou 215123, China.
| |
Collapse
|
106
|
Sattarahmady N, Azarpira N, Hosseinpour A, Heli H, Zare T. Albumin coated arginine-capped magnetite nanoparticles as a paclitaxel vehicle: Physicochemical characterizations and in vitro evaluation. J Drug Deliv Sci Technol 2016. [DOI: 10.1016/j.jddst.2016.07.004] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
107
|
Wadajkar AS, Dancy JG, Hersh DS, Anastasiadis P, Tran NL, Woodworth GF, Winkles JA, Kim AJ. Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2016; 9. [PMID: 27813323 DOI: 10.1002/wnan.1439] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/15/2016] [Revised: 08/28/2016] [Accepted: 09/15/2016] [Indexed: 12/29/2022]
Abstract
Glioblastoma (GBM) is a highly aggressive and lethal form of primary brain cancer. Numerous barriers exist to the effective treatment of GBM including the tightly controlled interface between the bloodstream and central nervous system termed the 'neurovascular unit,' a narrow and tortuous tumor extracellular space containing a dense meshwork of proteins and glycosaminoglycans, and genomic heterogeneity and instability. A major goal of GBM therapy is achieving sustained drug delivery to glioma cells while minimizing toxicity to adjacent neurons and glia. Targeted nanotherapeutics have emerged as promising drug delivery systems with the potential to improve pharmacokinetic profiles and therapeutic efficacy. Some of the key cell surface molecules that have been identified as GBM targets include the transferrin receptor, low-density lipoprotein receptor-related protein, αv β3 integrin, glucose transporter(s), glial fibrillary acidic protein, connexin 43, epidermal growth factor receptor (EGFR), EGFR variant III, interleukin-13 receptor α chain variant 2, and fibroblast growth factor-inducible factor 14. However, most targeted therapeutic formulations have yet to demonstrate improved efficacy related to disease progression or survival. Potential limitations to current targeted nanotherapeutics include: (1) adhesive interactions with nontarget structures, (2) low density or prevalence of the target, (3) lack of target specificity, and (4) genetic instability resulting in alterations of either the target itself or its expression level in response to treatment. In this review, we address these potential limitations in the context of the key GBM targets with the goal of advancing the understanding and development of targeted nanotherapeutics for GBM. WIREs Nanomed Nanobiotechnol 2017, 9:e1439. doi: 10.1002/wnan.1439 For further resources related to this article, please visit the WIREs website.
Collapse
Affiliation(s)
- Aniket S Wadajkar
- Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD, USA.,Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Jimena G Dancy
- Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD, USA.,Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA
| | - David S Hersh
- Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Pavlos Anastasiadis
- Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Nhan L Tran
- Departments of Cancer Biology and Neurosurgery, Mayo Clinic Arizona, Scottsdale, AZ, USA
| | - Graeme F Woodworth
- Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD, USA.,Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Jeffrey A Winkles
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.,Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.,Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Anthony J Kim
- Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD, USA.,Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.,Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA.,Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA.,Center for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, MD, USA
| |
Collapse
|
108
|
Sonali, Singh RP, Sharma G, Kumari L, Koch B, Singh S, Bharti S, Rajinikanth PS, Pandey BL, Muthu MS. RGD-TPGS decorated theranostic liposomes for brain targeted delivery. Colloids Surf B Biointerfaces 2016; 147:129-141. [DOI: 10.1016/j.colsurfb.2016.07.058] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2016] [Revised: 07/25/2016] [Accepted: 07/28/2016] [Indexed: 12/27/2022]
|
109
|
Esfandyari-Manesh M, Mohammadi A, Atyabi F, Nabavi SM, Ebrahimi SM, Shahmoradi E, Varnamkhasti BS, Ghahremani MH, Dinarvand R. Specific targeting delivery to MUC1 overexpressing tumors by albumin-chitosan nanoparticles conjugated to DNA aptamer. Int J Pharm 2016; 515:607-615. [PMID: 27989825 DOI: 10.1016/j.ijpharm.2016.10.066] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Revised: 10/21/2016] [Accepted: 10/27/2016] [Indexed: 01/04/2023]
Abstract
Chitosan-coated human serum albumin nanoparticles were functionalized by MUC1 aptamer to obtain a selective drug carrier toward cancers overexpressing MUC1. The negative charges of albumin nanoparticles were shifted to positive charges by surface modification with chitosan, and MUC1 was conjugated through an acrylate spacer. The cytotoxicity of targeted nanoparticles was significantly more than non-aptamer nanoparticles, and also the chitosan-coated nanoparticles had more cytotoxic effects than the negatively charged albumin nanoparticles. The IC50 of targeted nanoparticles was 28 and 26% of free paclitaxel in MCF7 and T47D cells at 48h, respectively. Confocal laser scanning electron microscopy showed that aptamer conjugation and positive charge increase the cellular uptake. 66% of paclitaxel was released within 32h, but 100% of drug was released at pH=5.5 (similar cancer cells). The paclitaxel plasma amount was at a good level of 17.6% at 2h for increasing the chance of cellular uptake.
Collapse
Affiliation(s)
- Mehdi Esfandyari-Manesh
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Ali Mohammadi
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Fatemeh Atyabi
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Seyedeh Maryam Nabavi
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Elnaz Shahmoradi
- Department of Chemical Engineering, Sharif University of Technology, Tehran, Iran
| | - Behrang Shiri Varnamkhasti
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Mohammad Hossein Ghahremani
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Rassoul Dinarvand
- Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
110
|
Ragelle H, Danhier F, Préat V, Langer R, Anderson DG. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert Opin Drug Deliv 2016; 14:851-864. [DOI: 10.1080/17425247.2016.1244187] [Citation(s) in RCA: 156] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Héloïse Ragelle
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
- Department of Anesthesiology, Boston Children’s Hospital, Boston, MA, USA
| | - Fabienne Danhier
- Advanced Drug Delivery and Biomaterial, Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium
| | - Véronique Préat
- Advanced Drug Delivery and Biomaterial, Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium
| | - Robert Langer
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- Harvard-MIT Division of Health Sciences & Technology, Massachusetts Institute of Technology, Cambridge, MA, USA
- Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA
- Division of Health Science Technology, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Daniel G. Anderson
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- Harvard-MIT Division of Health Sciences & Technology, Massachusetts Institute of Technology, Cambridge, MA, USA
- Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA
- Division of Health Science Technology, Massachusetts Institute of Technology, Cambridge, MA, USA
| |
Collapse
|
111
|
Wyss P, Herrera LC, Bouteghmes NS, Sarem M, Reichardt W, Leupold J, Hennig J, Shastri VP. Nanoprobes for Multimodal Visualization of Bone Mineral Phase in Magnetic Resonance and Near-Infrared Optical Imaging. ACS OMEGA 2016; 1:182-192. [PMID: 30023476 PMCID: PMC6044643 DOI: 10.1021/acsomega.6b00088] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Accepted: 07/27/2016] [Indexed: 05/31/2023]
Abstract
Imaging agents with affinity for bone can enable early detection of changes to bone mineral density, which is a hallmark of many bone-associated pathologies such as Paget's disease and osteoporosis. Here, we report the development of a polymer nanoparticle (NP)-based multimodal imaging probe that enables visualization of bone mineral phase in near-infrared (NIR) optical tomography and detection in T2-weighted magnetic resonance imaging (MRI). Ultrasmall superparamagnetic iron oxide was first encapsulated in NPs derived by blending poly(dl-lactic-co-glycolic acid)-poly(ethylene glycol) (PLGA-PEG) with N-hydroxysuccinimide functionalized-PLGA (NHS-PLGA). Postmodification of NHS surface functionality on the NPs with alendronic acid (Aln), a bone-targeting ligand, yielded stable ultrasmall superparamagnetic iron oxide nanoparticles (USPIONs) containing NPs that exhibit good serum stability and favorable cytocompatibility. These post-Aln-modified NPs exhibit 8- to 10-fold higher affinity for synthetic and biogenic hydroxyapatite in comparison to NPs where Aln was introduced before NP formation and shorten the T2 relaxation times in both agarose phantoms and fresh spongy bone, thus enabling the interrogation of bone mineral phase in T2-MRI. Finally, by introducing an NIR-dye-modified PLGA during the NP formation step, NP probes that enable the visualization of bone mineral phase in both NIR optical tomography and MRI have been realized. The system presented herein meets many of the criteria for clinical translation and therefore opens new opportunities for bone imaging and targeted therapeutics.
Collapse
Affiliation(s)
- Pradeep
P. Wyss
- Institute
for Macromolecular Chemistry, University
of Freiburg, Stefan Meier
Strasse 31, 79104 Freiburg, Germany
| | - Laura C. Herrera
- Institute
for Macromolecular Chemistry, University
of Freiburg, Stefan Meier
Strasse 31, 79104 Freiburg, Germany
| | - Nel S. Bouteghmes
- Institute
for Macromolecular Chemistry, University
of Freiburg, Stefan Meier
Strasse 31, 79104 Freiburg, Germany
- Université
Pierre et Marie Curie, 4 Place Jussieu, 75005 Paris, France
| | - Melika Sarem
- Institute
for Macromolecular Chemistry, University
of Freiburg, Stefan Meier
Strasse 31, 79104 Freiburg, Germany
- Helmholtz
Virtual Institute on Multifunctional Biomaterials for Medicine, Kantstrasse 55, 14513 Teltow, Germany
- BIOSS
− Centre for Biological Signaling Studies, University of Freiburg, Schänzlestrasse 18, 79104 Freiburg, Germany
| | - Wilfried Reichardt
- German
Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
- Radiology-Medical
Physics, University Medical Center Freiburg, Breisacher Strasse 60a, 79106 Freiburg, Germany
| | - Jochen Leupold
- Radiology-Medical
Physics, University Medical Center Freiburg, Breisacher Strasse 60a, 79106 Freiburg, Germany
| | - Jürgen Hennig
- Radiology-Medical
Physics, University Medical Center Freiburg, Breisacher Strasse 60a, 79106 Freiburg, Germany
| | - V. Prasad Shastri
- Institute
for Macromolecular Chemistry, University
of Freiburg, Stefan Meier
Strasse 31, 79104 Freiburg, Germany
- Helmholtz
Virtual Institute on Multifunctional Biomaterials for Medicine, Kantstrasse 55, 14513 Teltow, Germany
- BIOSS
− Centre for Biological Signaling Studies, University of Freiburg, Schänzlestrasse 18, 79104 Freiburg, Germany
| |
Collapse
|
112
|
|
113
|
Gilad Y, Firer M, Gellerman G. Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells. Biomedicines 2016; 4:E11. [PMID: 28536378 PMCID: PMC5344250 DOI: 10.3390/biomedicines4020011] [Citation(s) in RCA: 61] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Revised: 05/16/2016] [Accepted: 05/23/2016] [Indexed: 12/21/2022] Open
Abstract
Targeted delivery of chemotherapeutics and diagnostic agents conjugated to carrier ligands has made significant progress in recent years, both in regards to the structural design of the conjugates and their biological effectiveness. The goal of targeting specific cell surface receptors through structural compatibility has encouraged the use of peptides as highly specific carriers as short peptides are usually non-antigenic, are structurally simple and synthetically diverse. Recent years have seen many developments in the field of peptide based drug conjugates (PDCs), particularly for cancer therapy, as their use aims to bypass off-target side-effects, reducing the morbidity common to conventional chemotherapy. However, no PDCs have as yet obtained regulatory approval. In this review, we describe the evolution of the peptide-based strategy for targeted delivery of chemotherapeutics and discuss recent innovations in the arena that should lead in the near future to their clinical application.
Collapse
Affiliation(s)
- Yosi Gilad
- Department of Chemical Sciences, Ariel University, Ariel 40700, Israel.
- Department of Chemical Engineering and Biotechnology, Ariel University, Ariel 40700, Israel.
| | - Michael Firer
- Department of Chemical Engineering and Biotechnology, Ariel University, Ariel 40700, Israel.
| | - Gary Gellerman
- Department of Chemical Sciences, Ariel University, Ariel 40700, Israel.
| |
Collapse
|
114
|
Esfandyari-Manesh M, Darvishi B, Ishkuh FA, Shahmoradi E, Mohammadi A, Javanbakht M, Dinarvand R, Atyabi F. Paclitaxel molecularly imprinted polymer-PEG-folate nanoparticles for targeting anticancer delivery: Characterization and cellular cytotoxicity. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2016; 62:626-33. [DOI: 10.1016/j.msec.2016.01.059] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/23/2014] [Revised: 12/24/2015] [Accepted: 01/24/2016] [Indexed: 01/24/2023]
|
115
|
Roy A, Li SD. Modifying the tumor microenvironment using nanoparticle therapeutics. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2016; 8:891-908. [PMID: 27038329 DOI: 10.1002/wnan.1406] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Revised: 02/24/2016] [Accepted: 03/04/2016] [Indexed: 12/21/2022]
Abstract
Treatment of cancer has come a long way from the initial 'radical surgeries' to the multimodality treatments. For the major part of the last century, cancer was considered as a monocellular disorder, and treatment strategies were designed according to that hypothesis. However, the mortality rate from cancer continued to be high and a comprehensive treatment remained elusive. Recent progress in research has demonstrated that tumors are a complex network of neoplastic and non-neoplastic cells. The non-neoplastic cells, which are collectively called stroma, assist in tumor survival and progression. It has been shown that disrupting the tumor-stromal balance leads to significant effects on the tumor survival, and effective treatment can be achieved by targeting one or more of the stromal components. In this review, we summarize the roles of various stromal components in promoting tumor progression, and discuss innovative nanoparticle-mediated drug targeting strategies for stromal depletion and the subsequent effects on the tumors. Perspectives and the future directions are also provided. WIREs Nanomed Nanobiotechnol 2016, 8:891-908. doi: 10.1002/wnan.1406 For further resources related to this article, please visit the WIREs website.
Collapse
Affiliation(s)
- Aniruddha Roy
- Department of Pharmacy, Birla Institute of Technology & Science (BITS), Pilani, India.
| | - Shyh-Dar Li
- Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada.
| |
Collapse
|
116
|
Wu X, Han Z, Schur RM, Lu ZR. Targeted Mesoporous Silica Nanoparticles Delivering Arsenic Trioxide with Environment Sensitive Drug Release for Effective Treatment of Triple Negative Breast Cancer. ACS Biomater Sci Eng 2016; 2:501-507. [DOI: 10.1021/acsbiomaterials.5b00398] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Xiaohui Wu
- Department
of Biomedical
Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Zheng Han
- Department
of Biomedical
Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Rebecca M. Schur
- Department
of Biomedical
Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| | - Zheng-Rong Lu
- Department
of Biomedical
Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States
| |
Collapse
|
117
|
Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2016; 60:569-578. [DOI: 10.1016/j.msec.2015.11.067] [Citation(s) in RCA: 307] [Impact Index Per Article: 38.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Revised: 10/30/2015] [Accepted: 11/24/2015] [Indexed: 12/13/2022]
|
118
|
Li J, Zhang X, Wang M, Li X, Mu H, Wang A, Liu W, Li Y, Wu Z, Sun K. Synthesis of a bi-functional dendrimer-based nanovehicle co-modified with RGDyC and TAT peptides for neovascular targeting and penetration. Int J Pharm 2016; 501:112-23. [PMID: 26828670 DOI: 10.1016/j.ijpharm.2016.01.068] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Revised: 01/14/2016] [Accepted: 01/27/2016] [Indexed: 10/22/2022]
Abstract
The dual-ligand dendritic polyamidoamine-(polyethylene glycol)n-cyclic RGDyC peptide-(TAT peptide) (PPnR(T)) with various supplied molar ratios of polyethylene glycol (PEG) to polyamidoamine (PAMAM) (n=5, 15, 30) were designed as drug-carriers for the treatment of neovascular diseases; their targeting and penetrating effects were subsequently evaluated. (1)H NMR demonstrated PPnR(T) was successfully synthesized. Compared with the unmodified PAMAM, in vitro cytotoxicity of PPnR(T) to αvβ3 negative cells (αvβ3-) was significantly reduced, whereas the lethality to pathologic neovascular endothelial cells (αvβ3+) was efficiently increased compared to PPn. Compared to PP5R(T) and PP15R(T), PP30R(T) exhibited the most selective and efficient cellular uptake by human umbilical vein endothelial cells (HUVECs, αvβ3+). Membrane interaction study indicated the cellular uptake process of PP30R(T) of HUVECs mainly involved specific RGD-αvβ3 recognition as well as electrostatic interactions. Intracellular localization results confirmed PP30R(T) was distributed in the cytoplasm in HUVECs. 3D tumor spheroids penetration studies demonstrated that PP30R(T) penetrated the A549 cells to reach the depths of the avascular tumor spheroids. In vivo imaging further demonstrated that PP30R(T) achieved profoundly improved distribution in tumor tissues where angiogenesis existed. Therefore, the bi-functional dendrimer PP30R(T) displayed great potential as a nano-carrier for targeted drug delivery both in vitro and in vivo, and had broad prospects as nanocarriers for the targeted treatment of neovascular diseases.
Collapse
Affiliation(s)
- Jingjing Li
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai 264005, PR China
| | - Xuemei Zhang
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai 264005, PR China; Luye Pharmaceutical Co., Ltd., Shandong Province, PR China
| | - Meng Wang
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai 264005, PR China
| | - Xuejuan Li
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai 264005, PR China
| | - Hongjie Mu
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai 264005, PR China
| | - Aiping Wang
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai 264005, PR China
| | - Wanhui Liu
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai 264005, PR China; State Key Laboratory of Long-acting and Targeting Drug Delivery System, Yantai, Shandong Province, PR China; Luye Pharmaceutical Co., Ltd., Shandong Province, PR China
| | - Youxin Li
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai 264005, PR China; State Key Laboratory of Long-acting and Targeting Drug Delivery System, Yantai, Shandong Province, PR China; Luye Pharmaceutical Co., Ltd., Shandong Province, PR China
| | - Zimei Wu
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai 264005, PR China.
| | - Kaoxiang Sun
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai 264005, PR China.
| |
Collapse
|
119
|
Karathanasis E, Ghaghada KB. Crossing the barrier: treatment of brain tumors using nanochain particles. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2016; 8:678-95. [PMID: 26749497 DOI: 10.1002/wnan.1387] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Revised: 11/25/2015] [Accepted: 12/09/2015] [Indexed: 12/24/2022]
Abstract
Despite advancements in surgery and radiotherapy, the aggressive forms of brain tumors, such as gliomas, are still uniformly lethal with current therapies offering only palliation complicated by significant toxicities. Gliomas are characteristically diffuse with infiltrating edges, resistant to drugs and nearly inaccessible to systemic therapies due to the brain-tumor barrier. Currently, aggressive efforts are underway to further understand brain-tumor's microenvironment and identify brain tumor cell-specific regulators amenable to pharmacologic interventions. While new potent agents are continuously becoming available, efficient drug delivery to brain tumors remains a limiting factor. To tackle the drug delivery issues, a multicomponent chain-like nanoparticle has been developed. These nanochains are comprised of iron oxide nanospheres and a drug-loaded liposome chemically linked into a 100-nm linear, chain-like assembly with high precision. The nanochain possesses a unique ability to scavenge the tumor endothelium. By utilizing effective vascular targeting, the nanochains achieve rapid deposition on the vascular bed of glioma sites establishing well-distributed drug reservoirs on the endothelium of brain tumors. After reaching the target sites, an on-command, external low-power radiofrequency field can remotely trigger rapid drug release, due to mechanical disruption of the liposome, facilitating widespread and effective drug delivery into regions harboring brain tumor cells. Integration of the nanochain delivery system with the appropriate combination of complementary drugs has the potential to unfold the field and allow significant expansion of therapies for the disease where success is currently very limited. WIREs Nanomed Nanobiotechnol 2016, 8:678-695. doi: 10.1002/wnan.1387 For further resources related to this article, please visit the WIREs website.
Collapse
Affiliation(s)
- Efstathios Karathanasis
- Department of Biomedical Engineering and Department of Radiology, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA
| | - Ketan B Ghaghada
- Edward B. Singleton Department of Pediatric Radiology, Texas Children's Hospital, Department of Radiology, Baylor College of Medicine, Houston, TX, USA
| |
Collapse
|
120
|
Affiliation(s)
- Quanyin Hu
- Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina 27695, United States
- Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
- Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolin 27599, United States
| | - Zhen Gu
- Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina 27695, United States
- Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
- Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolin 27599, United States
| |
Collapse
|
121
|
Guan X, Hu X, Liu S, Sun X, Gai X. Cyclic RGD targeting cisplatin micelles for near-infrared imaging-guided chemotherapy. RSC Adv 2016. [DOI: 10.1039/c5ra19711b] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Nowadays imaging-guided chemotherapy is of great importance for developing highly efficient nanomedicines for cancer therapy.
Collapse
Affiliation(s)
- Xingang Guan
- Life Science Research Center
- Beihua University
- Jilin 132013
- P. R. China
- State Key Laboratory of Polymer Physics and Chemistry
| | - Xiuli Hu
- State Key Laboratory of Polymer Physics and Chemistry
- Changchun Institute of Applied Chemistry
- Chinese Academy of Sciences
- Changchun 130022
- P. R. China
| | - Shi Liu
- State Key Laboratory of Polymer Physics and Chemistry
- Changchun Institute of Applied Chemistry
- Chinese Academy of Sciences
- Changchun 130022
- P. R. China
| | - Xin Sun
- Life Science Research Center
- Beihua University
- Jilin 132013
- P. R. China
| | - Xiaodong Gai
- School of Basic Medical Sciences
- Beihua University
- Jilin 132013
- P. R. China
| |
Collapse
|
122
|
cRGDyK modified pH responsive nanoparticles for specific intracellular delivery of doxorubicin. Acta Biomater 2016; 30:285-298. [PMID: 26602824 DOI: 10.1016/j.actbio.2015.11.037] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2015] [Revised: 11/16/2015] [Accepted: 11/18/2015] [Indexed: 12/16/2022]
Abstract
Stimuli-responsive nanocarriers attract wide attention because of the unique differences in microenvironment between solid tumors and normal tissues. Herein, we reported a novel cRGDyK peptide modified pH-sensitive nanoparticle system based on poly(ethylene glycol)-poly(2,4,6-trimethoxy benzylidene-pentaerythritol carbonate) (PEG-PTMBPEC) diblock copolymer, which was expected to destroy tumor angiogenesis and kill tumor cells simultaneously. Doxorubicin (DOX)-loaded nanoparticles (NPs) were characterized to have a uniform size distribution, high entrapment efficiency, good stability in plasma as well as a pH dependent drug release pattern. Blank NPs were non-toxic to both tumor cells and normal cells, while DOX-loaded cRGDyK peptide modified NPs (cRGDyK-NPs) exhibited the pronounced cytotoxicity against B16 cells and human umbilical vein endothelial cells (HUVEC) overexpressing αvβ3 integrin receptors. Cellular uptake studies revealed that the highly efficient uptake of cRGDyK-NPs was attributed to the receptor-mediated endocytosis and acidic-triggered drug release. Importantly, cRGDyK-NPs could dramatically reduce the systemic toxicity of DOX and exert excellent tumor killing activity in vivo. The cRGDyK modified pH-sensitive nanocarrier is a promising vehicle for intracellular drug delivery to αvβ3 integrin receptor overexpressed tumor cells and neovascular cells. STATEMENT OF SIGNIFICANCE Slow intracellular drug release and poor tumor targeting capacity are still the critical barriers of polymeric nanoparticles (NPs) for the treatment efficiency of chemotherapy. In the present study, we designed cRGDyK peptide modified poly(ethylene glycol)-poly(2,4,6-trimethoxybenzylidene-pentaerythritol carbonate) (cRGDyK-PEG-PTMBPEC) NPs with active targeting and fast pH-triggered drug release. Doxorubicin (DOX)-loaded cRGDyK-PEG-PTMBPEC NPs exhibited pronounced cytotoxicity and enhanced cellular uptake against B16 cells and human umbilical vein endothelial cells overexpressing αvβ3 integrin receptors. Moreover, the active targeted pH-sensitive NPs can enhance the antitumor activity and reduce the systematic toxicity of DOX in vivo.
Collapse
|
123
|
Gilad Y, Noy E, Senderowitz H, Albeck A, Firer MA, Gellerman G. Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery. Bioorg Med Chem 2015; 24:294-303. [PMID: 26719208 DOI: 10.1016/j.bmc.2015.12.020] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2015] [Revised: 12/07/2015] [Accepted: 12/11/2015] [Indexed: 01/22/2023]
Abstract
New cyclic RGD peptide-anticancer agent conjugates, with different chemical functionalities attached to the parent peptide were synthesized in order to evaluate their biological activities and to provide a comparative study of their drug release profiles. The Integrin binding c(RGDfK) penta-peptide was used for the synthesis of Camptothecin (CPT) carbamate and Chlorambucil (CLB) amide conjugates. Substitution of the amino acid Lys with Ser resulted in a modified c(RGDfS) with a new attachment site, which enabled the synthesis of an ester CLB conjugate. Functional versatility of the conjugates was reflected in the variability of their drug release profiles, while the conserved RGD sequence of a selective binding to the αv integrin family, likely preserved their recognition by the Integrin and consequently their favorable toxicity towards targeted cancer cells. This hypothesis was supported by a computational analysis suggesting that all conjugates occupy conformational spaces similar to that of the Integrin bound bio-active parent peptide.
Collapse
Affiliation(s)
- Y Gilad
- Department of Biological Chemistry, Ariel University, Ariel 40700, Israel; The Julius Spokojny Bioorganic Chemistry Laboratory, Department of Chemistry, Bar Ilan University, Ramat Gan 52900, Israel
| | - E Noy
- Department of Chemistry, Bar Ilan University, Ramat Gan 52900, Israel
| | - H Senderowitz
- Department of Chemistry, Bar Ilan University, Ramat Gan 52900, Israel
| | - A Albeck
- The Julius Spokojny Bioorganic Chemistry Laboratory, Department of Chemistry, Bar Ilan University, Ramat Gan 52900, Israel
| | - M A Firer
- Department of Chemical Engineering, Ariel University, Ariel 40700, Israel
| | - G Gellerman
- Department of Biological Chemistry, Ariel University, Ariel 40700, Israel.
| |
Collapse
|
124
|
Hu X, Guan X, Li J, Pei Q, Liu M, Xie Z, Jing X. Hybrid polymer micelles capable of cRGD targeting and pH-triggered surface charge conversion for tumor selective accumulation and promoted uptake. Chem Commun (Camb) 2015; 50:9188-91. [PMID: 24995506 DOI: 10.1039/c4cc04056b] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
This study presents both tumor-targeting ligands (cRGD) and pH-activated surface charge-conversional moiety (imidazole) decorated micelles for Dox delivery. cRGD is expected to induce preferential tumor accumulation, while imidazole switches on positive charge in a tumor acid environment, which leads to enhanced micelle uptake by tumor cells.
Collapse
Affiliation(s)
- Xiuli Hu
- State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, P. R. China.
| | | | | | | | | | | | | |
Collapse
|
125
|
Shi Y, Zhou M, Zhang J, Lu W. Preparation and cellular targeting study of VEGF-conjugated PLGA nanoparticles. J Microencapsul 2015; 32:699-704. [PMID: 26004370 DOI: 10.3109/02652048.2015.1035683] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Vascular endothelial growth factor receptor (VEGFR) is over-expressed on a variety of tumour cells and tumour neovasculature, and so becomes well-documented target for cancer treatment. This study was designed to evaluate the cellular targeting and anti-tumor potency of VEGF-conjugated nanoparticles (VEGF-NPs). The poly-lactic-co-glycolic acid nanoparticles were prepared using the emulsion-solvent evaporation method and the VEGF was conjugated on surface of nanoparticles by covalent coupling method. The obtained particles were found to be of spherical shape exhibiting a size of 710 nm and VEGF conjugation efficiency was 16.6%. The results in vitro test showed that VEGF-NPs were more associated to Human Umbilical Vein Endothelial Cells by binding to VEGFR. In vitro cell proliferation test, IC50 showed the superior antiproliferative activity of paclitaxel-loaded VEGF-NPs over unconjugated nanoparticles and native paclitaxel due to higher cellular association on tumour cells. So, the VEGF-NPs offer a promising active targeting carrier for tumour selective treatment.
Collapse
Affiliation(s)
- Yaling Shi
- a School of Pharmacy, Health Science Center, Xi'an Jiaotong University , Xi'an , Shaanxi Province , RP China
| | - Mingyao Zhou
- a School of Pharmacy, Health Science Center, Xi'an Jiaotong University , Xi'an , Shaanxi Province , RP China
| | - Jie Zhang
- a School of Pharmacy, Health Science Center, Xi'an Jiaotong University , Xi'an , Shaanxi Province , RP China
| | - Wen Lu
- a School of Pharmacy, Health Science Center, Xi'an Jiaotong University , Xi'an , Shaanxi Province , RP China
| |
Collapse
|
126
|
Nanomedicine applied to translational oncology: A future perspective on cancer treatment. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2015; 12:81-103. [PMID: 26370707 DOI: 10.1016/j.nano.2015.08.006] [Citation(s) in RCA: 151] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/10/2015] [Revised: 07/17/2015] [Accepted: 08/27/2015] [Indexed: 01/08/2023]
Abstract
The high global incidence of cancer is associated with high rates of mortality and morbidity worldwide. By taking advantage of the properties of matter at the nanoscale, nanomedicine promises to develop innovative drugs with greater efficacy and less side effects than standard therapies. Here, we discuss both clinically available anti-cancer nanomedicines and those en route to future clinical application. The properties, therapeutic value, advantages and limitations of these nanomedicine products are highlighted, with a focus on their increased performance versus conventional molecular anticancer therapies. The main regulatory challenges toward the translation of innovative, clinically effective nanotherapeutics are discussed, with a view to improving current approaches to the clinical management of cancer. Ultimately, it becomes clear that the critical steps for clinical translation of nanotherapeutics require further interdisciplinary and international effort, where the whole stakeholder community is involved from bench to bedside. From the Clinical Editor: Cancer is a leading cause of mortality worldwide and finding a cure remains the holy-grail for many researchers and clinicians. The advance in nanotechnology has enabled novel strategies to develop in terms of cancer diagnosis and therapy. In this concise review article, the authors described current capabilities in this field and outlined comparisons with existing drugs. The difficulties in bringing new drugs to the clinics were also discussed.
Collapse
|
127
|
Boix-Garriga E, Acedo P, Casadó A, Villanueva A, Stockert JC, Cañete M, Mora M, Sagristá ML, Nonell S. Poly(D, L-lactide-co-glycolide) nanoparticles as delivery agents for photodynamic therapy: enhancing singlet oxygen release and photototoxicity by surface PEG coating. NANOTECHNOLOGY 2015; 26:365104. [PMID: 26293792 DOI: 10.1088/0957-4484/26/36/365104] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Poly(D, L-lactide-co-glycolide) (PLGA) nanoparticles (NPs) are being considered as nanodelivery systems for photodynamic therapy. The physico-chemical and biological aspects of their use remain largely unknown. Herein we report the results of a study of PLGA NPs for the delivery of the model hydrophobic photosensitizer ZnTPP to HeLa cells. ZnTPP was encapsulated in PLGA with high efficiency and the NPs showed negative zeta potentials and diameters close to 110 nm. Poly(ethylene glycol) (PEG) coating, introduced to prevent opsonization and clearance by macrophages, decreased the size and zeta potential of the NPs by roughly a factor of two and improved their stability in the presence of serum proteins. Photophysical studies revealed two and three populations of ZnTPP and singlet oxygen in uncoated and PEGylated NPs, respectively. Singlet oxygen is confined within the NPs in bare PLGA while it is more easily released into the external medium after PEG coating, which contributes to a higher photocytotoxicity towards HeLa cells in vitro. PLGA NPs are internalized by endocytosis, deliver their cargo to lysosomes and induce cell death by apoptosis upon exposure to light. In conclusion, PLGA NPs coated with PEG show high potential as delivery systems for photodynamic applications.
Collapse
Affiliation(s)
- Ester Boix-Garriga
- Grup d'Enginyeria Molecular, Institut Químic de Sarrià, Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
128
|
Future Perspectives of Radionanomedicine Using the Novel Micelle-Encapsulation Method for Surface Modification. Nucl Med Mol Imaging 2015; 49:170-3. [PMID: 26279689 DOI: 10.1007/s13139-015-0358-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Revised: 07/19/2015] [Accepted: 07/21/2015] [Indexed: 12/26/2022] Open
Abstract
The emerging radionanomedicine has multifunctional and theranostic purposes. For these purposes, radionanomedicine should achieve the efficient and specific delivery of therapeutic agents by multifunctional characteristics, using low amounts of nanomaterials in vivo. Recent research on radiolabeled micelle-encapsulated nanomaterials has been made on the their efficacy and safety using a one-step surface modification method (Jeong's method). This one-step multifunctional approach to the nanoparticle can be the important challenge in producing effective nanoplatforms for cancer imaging and therapy.
Collapse
|
129
|
Saraf P, Li X, Wrischnik L, Jasti B. In Vitro and In Vivo Efficacy of Self-Assembling RGD Peptide Amphiphiles for Targeted Delivery of Paclitaxel. Pharm Res 2015; 32:3087-101. [PMID: 26063045 DOI: 10.1007/s11095-015-1689-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2014] [Accepted: 03/26/2015] [Indexed: 10/23/2022]
Abstract
PURPOSE The objective of this work was to compare the efficacy of self-assembling cyclic and linear RGD peptide amphiphiles as carriers for delivering paclitaxel to αvβ3 integrin overexpressing tumors. METHODS Linear (C18-ADA5-RGD) and cyclic (C18-ADA5-cRGDfK) peptide amphiphiles were synthesized and characterized for CMC, aggregation number and micelle stability using fluorescence spectroscopy methods. Size and morphology of micelles was studied using TEM. Fluorescence polarization and confocal microscopy assays were established to compare binding and internalization of micelles. The targeting efficacy was studied in A2058 cells using cytotoxicity assay as well as in vivo in melanoma xenograft mouse model. RESULTS The linear and cyclic RGD amphiphiles exhibited CMC of 25 and 8 μM, respectively, formed nano-sized spherical micelles and showed competitive binding to αvβ3 integrin protein. FITC-loaded RGD micelles rapidly internalized into A2058 melanoma cells. Paclitaxel-loaded RGD micelles exhibited higher cytotoxicity compared with free drug in A2058 cells in vitro as well as in vivo. CONCLUSION Cyclic RGD micelles exhibited better targeting efficacy but were less effective compared to linear RGD micelles as drug delivery vehicle due to lower drug solubilization capacity and lesser kinetic stability. Results from the study proved the effectiveness of self-assembling low molecular weight RGD amphiphiles as carriers for targeted delivery of paclitaxel.
Collapse
Affiliation(s)
- Poonam Saraf
- Department of Pharmaceutics and Medicinal Chemistry, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, USA
| | | | | | | |
Collapse
|
130
|
Fernandes E, Ferreira JA, Andreia P, Luís L, Barroso S, Sarmento B, Santos LL. New trends in guided nanotherapies for digestive cancers: A systematic review. J Control Release 2015; 209:288-307. [PMID: 25957905 DOI: 10.1016/j.jconrel.2015.05.003] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2015] [Revised: 05/02/2015] [Accepted: 05/05/2015] [Indexed: 02/06/2023]
Abstract
Digestive tract tumors are among the most common and deadliest malignancies worldwide, mainly due to late diagnosis and lack of efficient therapeutics. Current treatments essentially rely on surgery associated with (neo)adjuvant chemotherapy agents. Despite an upfront response, conventional drugs often fail to eliminate highly aggressive clones endowed with chemoresistant properties, which are responsible for tumor recurrence and disease dissemination. Synthetic drugs also present severe adverse systemic effects, hampering the administration of biologically effective dosages. Nanoencapsulation of chemotherapeutic agents within biocompatible polymeric or lipid matrices holds great potential to improve the pharmacokinetics and efficacy of conventional chemotherapy while reducing systemic toxicity. Tagging nanoparticle surfaces with specific ligands for cancer cells, namely monoclonal antibodies or antibody fragments, has provided means to target more aggressive clones, further improving the selectivity and efficacy of nanodelivery vehicles. In fact, over the past twenty years, significant research has translated into a wide array of guided nanoparticles, providing the molecular background for a new generation of intelligent and more effective anti-cancer agents. Attempting to bring awareness among the medical community to emerging targeted nanopharmaceuticals and foster advances in the field, we have conducted a systematic review about this matter. Emphasis was set on ongoing preclinical and clinical trials for liver, colorectal, gastric and pancreatic cancers. To the best of our knowledge this is the first systematic and integrated overview on this field. Using a specific query, 433 abstracts were gathered and narrowed to 47 manuscripts when matched against inclusion/exclusion criteria. All studies showed that active targeting improves the effectiveness of the nanodrugs alone, while lowering its side effects. The main focus has been on hepatocarcinomas, mainly by exploring glycans as homing molecules. Other ligands such as peptides/small proteins and antibodies/antibody fragments, with affinity to either tumor vasculature or tumor cells, have also been widely and successfully applied to guide nanodrugs to gastrointestinal carcinomas. Conversely, few solutions have been presented for pancreatic tumors. To this date only three nanocomplexes have progressed beyond pre-clinical stages: i) PK2, a galactosamine-functionalized polymeric-DOX formulation for hepatocarcinomas; ii) MCC-465, an anti-(myosin heavy chain a) immunoliposome for advanced stage metastatic solid tumors; and iii) MBP-426, a transferrin-liposome-oxaliplatin conjugate, also for advanced stage tumors. Still, none has been approved for clinical use. However, based on the high amount of pre-clinical studies showing enthusiastic results, the number of clinical trials is expected to increase in the near future. A more profound understanding about the molecular nature of chemoresistant clones and cancer stem cell biology will also contribute to boost the field of guided nanopharmacology towards more effective solutions.
Collapse
Affiliation(s)
- Elisabete Fernandes
- Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal; I3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal and INEB - Instituto de Engenharia Biomédica, University of Porto, Porto, Portugal
| | - José Alexandre Ferreira
- Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal; Mass Spectrometry Center, QOPNA, Department of Chemistry, University of Aveiro, Aveiro, Portugal.
| | - Peixoto Andreia
- Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal
| | - Lima Luís
- Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal; Nucleo de Investigação em Farmácia - Centro de Investigação em Saúde e Ambiente (CISA), Health School of the Polytechnic Institute of Porto, Porto, Portugal
| | - Sérgio Barroso
- Serviço de Oncologia, Hospital de Évora, Évora, Portugal
| | - Bruno Sarmento
- I3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal and INEB - Instituto de Engenharia Biomédica, University of Porto, Porto, Portugal; CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Gandra PRD, Portugal
| | - Lúcio Lara Santos
- Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal; Health School of University of Fernando Pessoa, Porto, Portugal; Department of Surgical Oncology, Portuguese Institute of Oncology, Porto, Portugal
| |
Collapse
|
131
|
Li YJ, Dong M, Kong FM, Zhou JP. Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics. Int J Pharm 2015; 489:83-90. [PMID: 25888801 DOI: 10.1016/j.ijpharm.2015.04.028] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Revised: 03/25/2015] [Accepted: 04/13/2015] [Indexed: 02/04/2023]
Abstract
Nanoparticulate system with theranostic applications has attracted significant attention in cancer therapeutics. In the present study, we have developed a novel composite PLGA NP co-encapsulated with anticancer drug (sorafenib) and magnetic NP (SPION). We have successfully developed nanosized folate-conjugated PEGylated PLGA nanoparticles (SRF/FA-PEG-PLGA NP) with both anticancer and magnetic resonance property. We have showed that FA-conjugated NP exhibits sustained drug release and enhanced cellular uptake in BEL7402 cancer cells. The targeted NP effectively suppressed the tumor cell proliferation and has improved the anticancer efficacy than that of free drug or non-targeted one. Additionally, enhanced MRI properties demonstrate this formulation has good imaging agent characteristics. Finally, SRF/FA-PEG-PLGA NP effectively inhibited the colony forming ability indicating its superior anticancer effect. Together, these multifunctional nanoparticles would be most ideal to improve the therapeutic response in cancer and holds great potential to be a part of future nanomedicine. Our unique approach could be extended for multiple biomedical applications.
Collapse
Affiliation(s)
- Yu-Ji Li
- Department of General Surgery, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, China.
| | - Ming Dong
- Department of General Surgery, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, China
| | - Fan-Min Kong
- Department of General Surgery, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, China
| | - Jian-Ping Zhou
- Department of General Surgery, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, China
| |
Collapse
|
132
|
Guan X, Guan X, Tong H, Ma J, Sun X. Target Delivery of Daunorubicin to Glioblastoma by Cyclic RGD-Linked PEG-PLA Micelles. JOURNAL OF MACROMOLECULAR SCIENCE PART A-PURE AND APPLIED CHEMISTRY 2015. [DOI: 10.1080/10601325.2015.1018816] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
133
|
Pourcelle V, Laurent S, Welle A, Vriamont N, Stanicki D, Vander Elst L, Muller RN, Marchand-Brynaert J. Functionalization of the PEG Corona of Nanoparticles by Clip Photochemistry in Water: Application to the Grafting of RGD Ligands on PEGylated USPIO Imaging Agent. Bioconjug Chem 2015; 26:822-9. [DOI: 10.1021/acs.bioconjchem.5b00041] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Vincent Pourcelle
- Institute
of Condensed Matter and Nanosciences, Université catholique de Louvain, Place Louis Pasteur 1 bte L4.01.02, 1348 Louvain-La-Neuve, Belgium
| | - Sophie Laurent
- Department
of General, Organic and Biomedical Chemistry, NMR and Molecular Imaging
Laboratory, University of Mons, B-7000 Mons, Belgium
- Center for Microscopy and Molecular Imaging (CMMI), Rue Adrienne Bolland, 8 B-6041 Gosselies, Belgium
| | - Alexandre Welle
- Institute
of Condensed Matter and Nanosciences, Université catholique de Louvain, Place Louis Pasteur 1 bte L4.01.02, 1348 Louvain-La-Neuve, Belgium
| | - Nicolas Vriamont
- Institute
of Condensed Matter and Nanosciences, Université catholique de Louvain, Place Louis Pasteur 1 bte L4.01.02, 1348 Louvain-La-Neuve, Belgium
| | - Dimitri Stanicki
- Department
of General, Organic and Biomedical Chemistry, NMR and Molecular Imaging
Laboratory, University of Mons, B-7000 Mons, Belgium
| | - Luce Vander Elst
- Department
of General, Organic and Biomedical Chemistry, NMR and Molecular Imaging
Laboratory, University of Mons, B-7000 Mons, Belgium
- Center for Microscopy and Molecular Imaging (CMMI), Rue Adrienne Bolland, 8 B-6041 Gosselies, Belgium
| | - Robert N. Muller
- Department
of General, Organic and Biomedical Chemistry, NMR and Molecular Imaging
Laboratory, University of Mons, B-7000 Mons, Belgium
- Center for Microscopy and Molecular Imaging (CMMI), Rue Adrienne Bolland, 8 B-6041 Gosselies, Belgium
| | - Jacqueline Marchand-Brynaert
- Institute
of Condensed Matter and Nanosciences, Université catholique de Louvain, Place Louis Pasteur 1 bte L4.01.02, 1348 Louvain-La-Neuve, Belgium
| |
Collapse
|
134
|
Lee YK, Lee TS, Song IH, Jeong HY, Kang SJ, Kim MW, Ryu SH, Jung IH, Kim JS, Park YS. Inhibition of pulmonary cancer progression by epidermal growth factor receptor-targeted transfection with Bcl-2 and survivin siRNAs. Cancer Gene Ther 2015; 22:335-43. [DOI: 10.1038/cgt.2015.18] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Revised: 02/26/2015] [Accepted: 02/27/2015] [Indexed: 01/20/2023]
|
135
|
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 2015; 93:52-79. [PMID: 25813885 DOI: 10.1016/j.ejpb.2015.03.018] [Citation(s) in RCA: 1000] [Impact Index Per Article: 111.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2014] [Revised: 03/13/2015] [Accepted: 03/16/2015] [Indexed: 02/08/2023]
Abstract
Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. It is characterized by uncontrolled cell proliferation and an absence of cell death that, except for hematological cancers, generates an abnormal cell mass or tumor. This primary tumor grows thanks to new vascularization and, in time, acquires metastatic potential and spreads to other body sites, which causes metastasis and finally death. Cancer is caused by damage or mutations in the genetic material of the cells due to environmental or inherited factors. While surgery and radiotherapy are the primary treatment used for local and non-metastatic cancers, anti-cancer drugs (chemotherapy, hormone and biological therapies) are the choice currently used in metastatic cancers. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which is a characteristic of the cancerous cells, but unfortunately, it also affects normal cells with fast proliferation rates, such as the hair follicles, bone marrow and gastrointestinal tract cells, generating the characteristic side effects of chemotherapy. The indiscriminate destruction of normal cells, the toxicity of conventional chemotherapeutic drugs, as well as the development of multidrug resistance, support the need to find new effective targeted treatments based on the changes in the molecular biology of the tumor cells. These novel targeted therapies, of increasing interest as evidenced by FDA-approved targeted cancer drugs in recent years, block biologic transduction pathways and/or specific cancer proteins to induce the death of cancer cells by means of apoptosis and stimulation of the immune system, or specifically deliver chemotherapeutic agents to cancer cells, minimizing the undesirable side effects. Although targeted therapies can be achieved directly by altering specific cell signaling by means of monoclonal antibodies or small molecules inhibitors, this review focuses on indirect targeted approaches that mainly deliver chemotherapeutic agents to molecular targets overexpressed on the surface of tumor cells. In particular, we offer a detailed description of different cytotoxic drug carriers, such as liposomes, carbon nanotubes, dendrimers, polymeric micelles, polymeric conjugates and polymeric nanoparticles, in passive and active targeted cancer therapy, by enhancing the permeability and retention or by the functionalization of the surface of the carriers, respectively, emphasizing those that have received FDA approval or are part of the most important clinical studies up to date. These drug carriers not only transport the chemotherapeutic agents to tumors, avoiding normal tissues and reducing toxicity in the rest of the body, but also protect cytotoxic drugs from degradation, increase the half-life, payload and solubility of cytotoxic agents and reduce renal clearance. Despite the many advantages of all the anticancer drug carriers analyzed, only a few of them have reached the FDA approval, in particular, two polymer-protein conjugates, five liposomal formulations and one polymeric nanoparticle are available in the market, in contrast to the sixteen FDA approval of monoclonal antibodies. However, there are numerous clinical trials in progress of polymer-protein and polymer-drug conjugates, liposomal formulations, including immunoliposomes, polymeric micelles and polymeric nanoparticles. Regarding carbon nanotubes or dendrimers, there are no FDA approvals or clinical trials in process up to date due to their unresolved toxicity. Moreover, we analyze in detail the more promising and advanced preclinical studies of the particular case of polymeric nanoparticles as carriers of different cytotoxic agents to active and passive tumor targeting published in the last 5 years, since they have a huge potential in cancer therapy, being one of the most widely studied nano-platforms in this field in the last years. The interest that these formulations have recently achieved is stressed by the fact that 90% of the papers based on cancer therapeutics with polymeric nanoparticles have been published in the last 6 years (PubMed search).
Collapse
|
136
|
Sharma B, Ma W, Adjei IM, Panyam J, Dimitrijevic S, Labhasetwar V. Nanoparticle-mediated p53 gene therapy for tumor inhibition. Drug Deliv Transl Res 2015; 1:43-52. [PMID: 22553503 DOI: 10.1007/s13346-010-0008-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The p53 tumor suppressor gene is mutated in 50% of human cancers, resulting in more aggressive disease with greater resistance to chemotherapy and radiation therapy. Advances in gene therapy technologies offer a promising approach to restoring p53 function. We have developed polymeric nanoparticles (NPs), based on poly (lactic-co-glycolic acid), that provide sustained intracellular delivery of plasmid DNA, resulting in sustained gene expression without vector-associated toxicity. Our previous studies with p53 gene-loaded NPs (p53NPs) demonstrated sustained antiproliferative effects in cancer cells in vitro. The objective of this study was to evaluate the efficacy of p53NPs in vivo. Tumor xenografts in mice were established with human p53-null prostate cancer cells. Animals were treated with p53NPs by either local (intratumoral injection) or systemic (intravenous) administration. Controls included saline, p53 DNA alone, and control NPs. Mice treated with local injections of p53NPs demonstrated significant tumor inhibition and improved animal survival compared with controls. Tumor inhibition corresponded to sustained and greater p53 gene and protein expression in tumors treated with p53NPs than with p53 DNA alone. A single intravenous dose of p53NPs was successful in reducing tumor growth and improving animal survival, although not to the same extent as with local injections. Imaging studies showed that NPs accumulate in tumor tissue after intravenous injection; however, further improvement in tumor targeting efficiency of p53NPs may be needed for better outcome. In conclusion, the NP-mediated p53 gene therapy is effective in tumor growth inhibition. NPs may be developed as nonviral vectors for cancer and other genetic diseases.
Collapse
Affiliation(s)
- Blanka Sharma
- Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
| | | | | | | | | | | |
Collapse
|
137
|
Danhier F, Danhier P, De Saedeleer CJ, Fruytier AC, Schleich N, Rieux AD, Sonveaux P, Gallez B, Préat V. Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors. Int J Pharm 2015; 479:399-407. [DOI: 10.1016/j.ijpharm.2015.01.009] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2014] [Revised: 01/06/2015] [Accepted: 01/07/2015] [Indexed: 01/01/2023]
|
138
|
Peiris PM, Abramowski A, Mcginnity J, Doolittle E, Toy R, Gopalakrishnan R, Shah S, Bauer L, Ghaghada KB, Hoimes C, Brady-Kalnay SM, Basilion JP, Griswold MA, Karathanasis E. Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle. Cancer Res 2015; 75:1356-65. [PMID: 25627979 DOI: 10.1158/0008-5472.can-14-1540] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2014] [Accepted: 01/04/2015] [Indexed: 01/05/2023]
Abstract
Glioblastoma multiforme is generally recalcitrant to current surgical and local radiotherapeutic approaches. Moreover, systemic chemotherapeutic approaches are impeded by the blood-tumor barrier. To circumvent limitations in the latter area, we developed a multicomponent, chain-like nanoparticle that can penetrate brain tumors, composed of three iron oxide nanospheres and one drug-loaded liposome linked chemically into a linear chain-like assembly. Unlike traditional small-molecule drugs or spherical nanotherapeutics, this oblong-shaped, flexible nanochain particle possessed a unique ability to gain access to and accumulate at glioma sites. Vascular targeting of nanochains to the αvβ3 integrin receptor resulted in a 18.6-fold greater drug dose administered to brain tumors than standard chemotherapy. By 2 hours after injection, when nanochains had exited the blood stream and docked at vascular beds in the brain, the application of an external low-power radiofrequency field was sufficient to remotely trigger rapid drug release. This effect was produced by mechanically induced defects in the liposomal membrane caused by the oscillation of the iron oxide portion of the nanochain. In vivo efficacy studies conducted in two different mouse orthotopic models of glioblastoma illustrated how enhanced targeting by the nanochain facilitates widespread site-specific drug delivery. Our findings offer preclinical proof-of-concept for a broadly improved method for glioblastoma treatment.
Collapse
Affiliation(s)
- Pubudu M Peiris
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio. Department of Radiology, Case Western Reserve University, Cleveland, Ohio. Case Center for Imaging Research, Case Western Reserve University, Cleveland, Ohio
| | - Aaron Abramowski
- Case Center for Imaging Research, Case Western Reserve University, Cleveland, Ohio. Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio
| | - James Mcginnity
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio. Case Center for Imaging Research, Case Western Reserve University, Cleveland, Ohio
| | - Elizabeth Doolittle
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio. Department of Radiology, Case Western Reserve University, Cleveland, Ohio. Case Center for Imaging Research, Case Western Reserve University, Cleveland, Ohio
| | - Randall Toy
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio. Department of Radiology, Case Western Reserve University, Cleveland, Ohio. Case Center for Imaging Research, Case Western Reserve University, Cleveland, Ohio
| | - Ramamurthy Gopalakrishnan
- Department of Radiology, Case Western Reserve University, Cleveland, Ohio. Case Center for Imaging Research, Case Western Reserve University, Cleveland, Ohio
| | - Shruti Shah
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio. Case Center for Imaging Research, Case Western Reserve University, Cleveland, Ohio
| | - Lisa Bauer
- Department of Radiology, Case Western Reserve University, Cleveland, Ohio. Case Center for Imaging Research, Case Western Reserve University, Cleveland, Ohio. Department of Physics, Case Western Reserve University, Cleveland, Ohio
| | - Ketan B Ghaghada
- Edward B. Singleton Department of Pediatric Radiology, Texas Children's Hospital, Houston, Texas. Department of Radiology, Baylor College of Medicine, Houston, Texas
| | - Christopher Hoimes
- University Hospitals Case Medical Center, Cleveland, Ohio. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio
| | - Susann M Brady-Kalnay
- Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio. Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio
| | - James P Basilion
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio. Department of Radiology, Case Western Reserve University, Cleveland, Ohio. Case Center for Imaging Research, Case Western Reserve University, Cleveland, Ohio. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio
| | - Mark A Griswold
- Department of Radiology, Case Western Reserve University, Cleveland, Ohio. Case Center for Imaging Research, Case Western Reserve University, Cleveland, Ohio. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio
| | - Efstathios Karathanasis
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio. Department of Radiology, Case Western Reserve University, Cleveland, Ohio. Case Center for Imaging Research, Case Western Reserve University, Cleveland, Ohio. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.
| |
Collapse
|
139
|
Guan X, Hu X, Li Z, Zhang H, Xie Z. cRGD targeted and charge conversion-controlled release micelles for doxorubicin delivery. RSC Adv 2015. [DOI: 10.1039/c4ra14368j] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A biodegradable polymeric micelle with cRGD targeting and charge-conversional moiety could enhance the cellular uptake of pharmaceuticals and result in high cytotoxicity to tumor cells.
Collapse
Affiliation(s)
- Xingang Guan
- State Key Laboratory of Polymer Physics and Chemistry
- Changchun Institute of Applied Chemistry
- Chinese Academy of Sciences
- Changchun 130022
- P. R. China
| | - Xiuli Hu
- State Key Laboratory of Polymer Physics and Chemistry
- Changchun Institute of Applied Chemistry
- Chinese Academy of Sciences
- Changchun 130022
- P. R. China
| | - Zhihong Li
- Department of Thoracic Surgery
- The First Hospital of Jilin University
- Changchun 130021
- P. R. China
| | - Hong Zhang
- Department of Thoracic Surgery
- The First Hospital of Jilin University
- Changchun 130021
- P. R. China
| | - Zhigang Xie
- State Key Laboratory of Polymer Physics and Chemistry
- Changchun Institute of Applied Chemistry
- Chinese Academy of Sciences
- Changchun 130022
- P. R. China
| |
Collapse
|
140
|
Su N, Dang Y, Liang G, Liu G. Iodine-125-labeled cRGD-gold nanoparticles as tumor-targeted radiosensitizer and imaging agent. NANOSCALE RESEARCH LETTERS 2015; 10:160. [PMID: 25883543 PMCID: PMC4393404 DOI: 10.1186/s11671-015-0864-9] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Accepted: 03/16/2015] [Indexed: 05/20/2023]
Abstract
Research interests on radiosensitive property of gold nanoparticles (GNPs) are rapidly raised because of the extensively proved in vitro effectiveness and clinical necessity. However, the issue of targeted accumulation of GNPs in tumor tissues hindered the transference to in vivo applications. In this study, hybrid nano-sized cyclic Arg-Gly-Asp-conjugated GNPs (cRGD-GNPs) integrated with radioactive iodine-125 was fabricated as tumor-targeted radiosensitizer. Therapeutic effects, including acute apoptosis (2 days post treatment) and long-term influence (up to 21 days), were investigated on NCI-H446 tumor-bearing mice via Tc-99 m-Annexin V SPECT and volume measurements, respectively. Apoptosis and volume loss were consistent in showing that tumor growth was effectively suppressed via the treatment of (125)I-cRGD-GNP sensitized radiotherapy (RT), a more significantly radiosensitive effect than the treatment of non-targeted GNPs with RT, RT treatment alone, and no treatment. SPECT/CT images showed that the uptake of cRGD-GNPs by tumor tissues reached the peak target/non-target value of 4.76 at around 2 h post injection, and dynamic radioactivity monitoring showed that (125)I-cRGD-GNPs maintained about 2.5% of injected dosage at 55 h post injection. For long-term influence, a significant radiosensitized RT-induced volume loss was observed. Hence, cyclic RGD conjugation makes the GNP-based radiosensitizer tumor targeting, offering a new modality for enhancing radiotherapeutic efficacy. Additionally, the introduction of I-125 serves as both a therapeutic factor and a radiotracer for in vivo tracking of GNPs.
Collapse
Affiliation(s)
- Ning Su
- />Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060 China
| | - Yajie Dang
- />Department of Respiratory Medicine, First People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, 201600 China
| | - Guangli Liang
- />Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060 China
| | - Guizhi Liu
- />Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060 China
| |
Collapse
|
141
|
Liang H, Huang Q, Zhou B, He L, Lin L, An Y, Li Y, Liu S, Chen Y, Li B. Self-assembled zein–sodium carboxymethyl cellulose nanoparticles as an effective drug carrier and transporter. J Mater Chem B 2015; 3:3242-3253. [DOI: 10.1039/c4tb01920b] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
In this work, biodegradable nanoparticles (NPs) were assembled with sodium carboxymethyl cellulose (CMC) and zein to produce zein–CMC NPs.
Collapse
|
142
|
Tang CY, Liao YH, Tan GS, Wang XM, Lu GH, Yang YH. Targeted photosensitizer nanoconjugates based on human serum albumin selectively kill tumor cells upon photo-irradiation. RSC Adv 2015. [DOI: 10.1039/c5ra05251c] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Small and non-toxic nanoconjugates RGD–HSA–Ce6 could provide targeted and effective photodynamic therapy of tumor cells.
Collapse
Affiliation(s)
- Cheng-Yi Tang
- State Key Laboratory of Pharmaceutical Biotechnology
- NJU-NJFU Joint Institute of Plant Molecular Biology
- School of Life Sciences
- Nanjing University
- Nanjing 210093
| | - Yong-hui Liao
- State Key Laboratory of Pharmaceutical Biotechnology
- NJU-NJFU Joint Institute of Plant Molecular Biology
- School of Life Sciences
- Nanjing University
- Nanjing 210093
| | - Guo-Sheng Tan
- State Key Laboratory of Pharmaceutical Biotechnology
- NJU-NJFU Joint Institute of Plant Molecular Biology
- School of Life Sciences
- Nanjing University
- Nanjing 210093
| | - Xiao-Ming Wang
- State Key Laboratory of Pharmaceutical Biotechnology
- NJU-NJFU Joint Institute of Plant Molecular Biology
- School of Life Sciences
- Nanjing University
- Nanjing 210093
| | - Gui-Hua Lu
- State Key Laboratory of Pharmaceutical Biotechnology
- NJU-NJFU Joint Institute of Plant Molecular Biology
- School of Life Sciences
- Nanjing University
- Nanjing 210093
| | - Yong-Hua Yang
- State Key Laboratory of Pharmaceutical Biotechnology
- NJU-NJFU Joint Institute of Plant Molecular Biology
- School of Life Sciences
- Nanjing University
- Nanjing 210093
| |
Collapse
|
143
|
Multifunctional Polymeric Nano-Carriers in Targeted Drug Delivery. ADVANCES IN DELIVERY SCIENCE AND TECHNOLOGY 2015. [DOI: 10.1007/978-3-319-11355-5_15] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
144
|
Cai M, Ye M, Shang X, Sun H, Liu M, Sun H, Ma Z, Zhu H. cRGD-functionalized redox-sensitive micelles as potential doxorubicin delivery carriers for αvβ3 integrin over expressing tumors. RSC Adv 2015. [DOI: 10.1039/c5ra16137a] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
The cRGD-modified redox-sensitive micelles as nanocarrier-based drug delivery provide an innovative platform for targeted integrin over expressing tumor cells anticancer drug delivery and offer better antitumour activity.
Collapse
Affiliation(s)
- Meng Cai
- School of Food and Pharmaceutical Engineering
- Key Laboratory of Fermentation Engineering (Ministry of Education)
- Hubei Provincial Cooperative Innovation Center of Industrial Fermentation
- Hubei University of Technology
- Wuhan 430068
| | - Mengyuan Ye
- School of Food and Pharmaceutical Engineering
- Key Laboratory of Fermentation Engineering (Ministry of Education)
- Hubei Provincial Cooperative Innovation Center of Industrial Fermentation
- Hubei University of Technology
- Wuhan 430068
| | - Xingxing Shang
- School of Food and Pharmaceutical Engineering
- Key Laboratory of Fermentation Engineering (Ministry of Education)
- Hubei Provincial Cooperative Innovation Center of Industrial Fermentation
- Hubei University of Technology
- Wuhan 430068
| | - Honghao Sun
- School of Food and Pharmaceutical Engineering
- Key Laboratory of Fermentation Engineering (Ministry of Education)
- Hubei Provincial Cooperative Innovation Center of Industrial Fermentation
- Hubei University of Technology
- Wuhan 430068
| | - Mingxing Liu
- School of Food and Pharmaceutical Engineering
- Key Laboratory of Fermentation Engineering (Ministry of Education)
- Hubei Provincial Cooperative Innovation Center of Industrial Fermentation
- Hubei University of Technology
- Wuhan 430068
| | - Hongmei Sun
- School of Food and Pharmaceutical Engineering
- Key Laboratory of Fermentation Engineering (Ministry of Education)
- Hubei Provincial Cooperative Innovation Center of Industrial Fermentation
- Hubei University of Technology
- Wuhan 430068
| | - Zhuo Ma
- School of Food and Pharmaceutical Engineering
- Key Laboratory of Fermentation Engineering (Ministry of Education)
- Hubei Provincial Cooperative Innovation Center of Industrial Fermentation
- Hubei University of Technology
- Wuhan 430068
| | - Hongda Zhu
- School of Food and Pharmaceutical Engineering
- Key Laboratory of Fermentation Engineering (Ministry of Education)
- Hubei Provincial Cooperative Innovation Center of Industrial Fermentation
- Hubei University of Technology
- Wuhan 430068
| |
Collapse
|
145
|
Danhier F, Kouhé TTB, Duhem N, Ucakar B, Staub A, Draoui N, Feron O, Préat V. Vitamin E-based micelles enhance the anticancer activity of doxorubicin. Int J Pharm 2014; 476:9-15. [DOI: 10.1016/j.ijpharm.2014.09.028] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2014] [Revised: 09/17/2014] [Accepted: 09/18/2014] [Indexed: 12/27/2022]
|
146
|
Comparison of active, passive and magnetic targeting to tumors of multifunctional paclitaxel/SPIO-loaded nanoparticles for tumor imaging and therapy. J Control Release 2014; 194:82-91. [DOI: 10.1016/j.jconrel.2014.07.059] [Citation(s) in RCA: 164] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2014] [Revised: 07/28/2014] [Accepted: 07/30/2014] [Indexed: 01/22/2023]
|
147
|
Wang X, Li S, Shi Y, Chuan X, Li J, Zhong T, Zhang H, Dai W, He B, Zhang Q. The development of site-specific drug delivery nanocarriers based on receptor mediation. J Control Release 2014; 193:139-53. [DOI: 10.1016/j.jconrel.2014.05.028] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2014] [Revised: 05/13/2014] [Accepted: 05/17/2014] [Indexed: 01/28/2023]
|
148
|
Wang S, Qiu J, Shi Z, Wang Y, Chen M. Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer. Biotechnol Adv 2014; 33:224-241. [PMID: 25447422 DOI: 10.1016/j.biotechadv.2014.10.011] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2014] [Revised: 10/15/2014] [Accepted: 10/23/2014] [Indexed: 02/07/2023]
Abstract
Taxanes are one type of the most extensively used chemotherapeutic agents to treat cancers. However, their clinical use is severely limited by intrinsic and acquired resistance. A diverse variety of mechanisms has been implicated about taxane resistance, such as alterations of drug targets, overexpression of efflux transporters, defective apoptotic machineries, and barriers in drug transport. The deepening understanding of molecular mechanisms of taxane resistance has spawned a number of targets for reversing resistance. However, circumvention of taxane resistance would not only possess therapeutic potential, but also face with clinical challenge, which accelerates the development of optimal nanoscale delivery systems. This review highlights the current understanding on the mechanisms of taxane resistance, and provides a comprehensive analysis of various nanoscale delivery systems to reverse taxane resistance.
Collapse
Affiliation(s)
- Shengpeng Wang
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China
| | - Jiange Qiu
- Department of Cell Biology and Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, China
| | - Zhi Shi
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China; Department of Cell Biology and Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, China.
| | - Yitao Wang
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China
| | - Meiwan Chen
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.
| |
Collapse
|
149
|
Geary SM, Salem AK. Exploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs. Crit Rev Oncog 2014; 19:269-80. [PMID: 25271435 DOI: 10.1615/critrevoncog.2014011518] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Tumor tissues possess characteristics that distinguish them from healthy tissues and make them attractive targets for submicron carriers of chemotherapeutic drugs (CTX). CTX are generally administered systemically in free form to cancer patients resulting in unwanted cytotoxic effects and placing limitations on the deliverable CTX dose. In an effort to raise the therapeutic index of CTX there are now liposome-based CTX formulations in clinical use that are more tumor specific than the free form of CTX. However, progression to liposome-based chemotherapy in the clinic has been slow and there have been no approved formulations introduced in the last decade. Alternative carrier systems such as those made from the biodegradable polymer poly(lactic-co-glycolic) acid (PLGA) have been investigated in preclinical settings with promising outcomes. Here we review the principle behind biodegradable submicron carriers as CTX delivery vehicles for solid tumors with a specific focUS on liposomes and PLGA-based carriers, highlighting the strengths and weaknesses of each system.
Collapse
Affiliation(s)
- Sean M Geary
- Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa
| | - Aliasger K Salem
- Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa
| |
Collapse
|
150
|
Sathler PC, Lourenço AL, Rodrigues CR, da Silva LCRP, Cabral LM, Jordão AK, Cunha AC, Vieira MCB, Ferreira VF, Carvalho-Pinto CE, Kang HC, Castro HC. In vitro and in vivo analysis of the antithrombotic and toxicological profile of new antiplatelets N-acylhydrazone derivatives and development of nanosystems. Thromb Res 2014; 134:376-83. [DOI: 10.1016/j.thromres.2014.05.009] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2013] [Revised: 04/04/2014] [Accepted: 05/06/2014] [Indexed: 11/24/2022]
|